Condition: Acute Lymphoblastic Leukemia · Sponsor: University College, London
This study aims to evaluate the safety, efficacy and duration of response of CD19+CD22 Chimeric Antigen Receptor (CAR) redirected autologous T-cells in children with high risk, relapsed CD19+ and CD22+ acute lymphoblastic leukaemia
This description comes directly from the study's public registry record.
Aniqa Tasnim · 0203 108 4753 · ctc.carpall@ucl.ac.uk
Always discuss trial participation with your own doctor first.
| Great Ormond Street Hospital | London, United Kingdom | Recruiting |
| University College Hospital | London, United Kingdom | Recruiting |
| Manchester Royal Children's Hospital | Manchester, United Kingdom | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT02443831